Hereditary Angioedema Types I and II

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456 | PHASE 3 | INTERVENTIONAL

The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin of subjects with hereditary angioedema. The safety of C1-esterase inhibitor will also be assessed. Each subject will enter a run-in period of up to 8-weeks. Subjects who complete the run-in period and who are eligible will then enter the treatment phase which comprises two sequential treatment periods. In the treatment phase, subjects will be randomized to one of four arms consisting of treatment with low- or higher-volume C1-esterase inhibitor in one treatment period and treatment with low- or higher-volume placebo in the other treatment period. The study will measure the number of hereditary angioedema attacks that subjects experience while receiving each treatment.

39 Sites

90 Participants

Recruiting

12 Years to 71 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

Birmingham,Alabama,United States,35209

Study Site

Scottsdale,Arizona,United States,85251

Study Site

Bell Gardens,California,United States,90201

Study Site

La Jolla,California,United States,92093

Study Site

Orange,California,United States,92868

Study Site

Walnut Creek,California,United States,94598

Study Site

Colorado Springs,Colorado,United States,80907

Study Site

Chevy Chase,Maryland,United States,20815

Study Site

Boston,Massachusetts,United States,02114

Study Site

Cincinnati,Ohio,United States,45267

Study Site

Columbus,Ohio,United States,43235

Study Site

Toledo,Ohio,United States,43617

Study Site

Tulsa,Oklahoma,United States,74136

Study Site

Lake Oswego,Oregon,United States,97035

Study Site

Hershey,Pennsylvania,United States,17033

Study Site

Dallas,Texas,United States,75231

Study Site

Richmond,Virginia,United States,23298

Study Site

Virginia Beach,Virginia,United States,23452

Study Site

Spokane,Washington,United States,99204

Study Site

Campbelltown,New South Wales,Australia,2560

Study Site

Hamilton,Ontario,Canada,L8N3Z5

Study Site

Ottawa,Ontario,Canada,K1Y4G2

Study Site

Toronto,Ontario,Canada,M4V1R2

Study Site

Quebec,Canada,G1V4M6

Study Site

Hradec Kralove,Czechia,50005

Study Site

Plzen,Czechia,30460

Study Site

Budapest,Hungary,1125

Study Site

Tel Aviv,Israel,64239

Study Site

Tel Hashomer,Israel,52621

Study Site

Catania,Italy,95123

Study Site

Palermo,Italy,90146

Study Site

Cluj Napoca,Romania,400139

Study Site

Mures,Romania,540103

Study Site

Barcelona,Spain,08035

Study Site

Madrid,Spain,28007

Study Site

Madrid,Spain,28046

Study Site

Valencia,Spain,46026

Study Site

Brighton,United Kingdom,BN25BE

Study Site

London,United Kingdom,E12ES

Study Eligibility Criteria

Inclusion Criteria

Run-In Period Inclusion Criteria:
* Males or females aged 12 years or older.
* A clinical diagnosis of hereditary angioedema type I or II.
* Hereditary angioedema attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment.
* For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of Screening: use of a stable regimen within 3 months of Screening, with no plans to change.
Eligibility Criteria for Entering Treatment Period 1:
* Laboratory confirmation of type I or type II hereditary angioedema, including C1-esterase inhibitor functional activity less than 50% AND C4 antigen level below the laboratory reference range.
* No clinically significant abnormalities as assessed using laboratory parameters.
* During participation in the run-in period, subjects must have experienced hereditary angioedema attacks that required acute treatment, required medical attention, or caused significant functional impairment.

Exclusion Criteria

Run-In Period Exclusion Criteria:
* History of clinical significant arterial or venous thrombosis, or current history of a clinically significant prothrombotic risk.
* Incurable malignancies at screening.
* Any clinical condition that will interfere with the evaluation of C1-esterase inhibitor therapy.
* Clinically significant history of poor response to C1-esterase therapy for the management of hereditary angioedema.
* Receiving therapy prohibited by the protocol, including medications for hereditary angioedema prophylaxis.
* Female subjects who started taking or changed dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progesterone-containing products) within 3 months prior to the screening visit.

Additional Studies

Additional studies can be found at ClinicalTrials.gov